Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4754 - CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Renal Cell Cancer


Cristina Masini


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


C. Masini1, M.G. Vitale1, M. Maruzzo2, G. Procopio3, U. De Giorgi4, S. Buti5, S. Rossetti6, R. Iacovelli7, A. Guida8, F. Atzori9, C. Mucciarini10, S. Scagliarini11, F. Vignani12, G. Prati13, L. Cosmai14, A. Berselli1, C. Pinto1

Author affiliations

  • 1 Oncology Unit, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 2 Oncology Unit, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 3 Oncology Unit, FONDAZIONE IRCCS INT MILANO, 20133 - Milano/IT
  • 4 Oncology Unit, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 5 Oncology Unit, Azienda Ospedaliera di Parma, 43126 - Parma/IT
  • 6 Division Of Medical Oncology, Department Of Uro-gynaecological Oncology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 7 Oncology Unit, Azienda ospedaliero universitaria integrata Verona, 37134 - Verona/IT
  • 8 Oncology Unit, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41100 - Modena/IT
  • 9 Oncology Unit, azienda ospedaliera-universitaria di Cagliari, 09100 - Cagliari/IT
  • 10 Medical Oncology, Ramazzini Hospital, 41012 - Carpi (Modena)/IT
  • 11 Oncology Unit, Azienda ospedaliera Antonio Cardarelli, 80131 - Napoli/IT
  • 12 Oncology Unit, A.O. Ordine Mauriziano, 10128 - Torino/IT
  • 13 Medical Oncology, A.O. Ordine Mauriziano, 42016 - Guastalla/IT
  • 14 Nephrology Unit, Istituti Ospitalieri Cremona, 26100 - Cremona/IT


Abstract 4754


Pazopanib has been approved for first-line treatment of patients (pts) with mRCC based on the prospective randomized trial that enrolled only pts with adequate renal function. There are no data on the efficacy and toxicity of pazopanib in pts with renal insufficiency (RI). The aim of this study is to investigate the effect of kidney function on treatment outcomes in pts treated with pazopanib for mRCC.


We retrospectively analyzed the data of the mRCC pts treated with pazopanib with respect to renal function in fourteen Italian institutions from January 2010 to June 2016. Baseline glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula at the time of therapy initiation. Pts with MDRD


Two hundred and twenty-nine pts with mRCC were included in this study: 128 pts in group A and 101 pts in group B. 68% of pts were male, median age was 67 years (34-88) and median CrCl was 49,7 ml/min in group A. In group B, 64% of pts were male, median age was 64 years (38-85) and median CrCl was 74 ml/min. Pts with MDRD


Although in this study it is necessary to reduce the dose of pazopanib more frequent in pts with RI, kidney function at therapy initiation does not adversely affect the efficacy and safety of pazopanib.

Clinical trial identification

Legal entity responsible for the study

Cristina Masini




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.